DrugPatentWatch Database Preview
Patent: 7,582,618
» See Plans and Pricing
Summary for Patent: 7,582,618
| Title: | 2\'-C-methyl-3\'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| Abstract: | The 3\'-L-valine ester of .beta.-D-2\'-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase. |
| Inventor(s): | Sommadossi; Jean-Pierre (Cambridge, MA), LaColla; Paolo (Capoterra, IT), Gosselin; Gilles (Montpellier, FR) |
| Assignee: | Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) |
| Application Number: | 11/516,928 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,582,618
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vidara Therapeutics Research Ltd | ACTIMMUNE | interferon gamma-1b | VIAL; SINGLE-USE | 103836 | 001 | 1999-02-25 | Start Trial | Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) | 2022-06-28 | RX | search | |
| Serono Inc | REBIF | interferon beta-1a | SYRINGE | 103780 | 002 | 2002-03-07 | Start Trial | Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) | 2022-06-28 | RX | search | |
| Serono Inc | REBIF | interferon beta-1a | SYRINGE | 103780 | 001 | 2002-03-07 | Start Trial | Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) | 2022-06-28 | RX | search | |
| Biogen | AVONEX | interferon beta-1a | VIAL | 103628 | 001 | 1996-05-17 | Start Trial | Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) | 2022-06-28 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 7,582,618
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200410249 | Start Trial |
| South Africa | 200410290 | Start Trial |
| South Africa | 200504954 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2004002422 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2004002999 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2004003000 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2004052899 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
